TABLE 4

K1 estimates for different CYP3A preparations obtained from inactivation experiments

Calculation of K1 was based on the loss of midazolam 1′-hydroxylation activity. Experiments were conducted with at least five inhibitor concentrations, preincubation times varying from 1 to 25 min, and with 8 μM midazolam. Human liver microsomal preparations contained predominantly CYP3A4 or CYP3A5, as described under Materials and Methods. Data for microsomes are reported as mean ± S.D. (except for erythromycin and CYP3A5, where data from only two livers could be fit to the inactivation model). Values for Supersomes are mean ± S.E. for the model fit. No statistical tests were performed for comparison of Supersomes.


Inhibitor

HL Microsomes

Supersomes
CYP3A4 (n = 3)
CYP3A5 (n = 2)
CYP3A4 + b5
CYP3A5 + b5
Erythromycin (μM) 10.9 ± 4.0 10.1 7.47 ± 3.0 7.14 ± 0.7
Diltiazem (μM) 18.1 ± 7.6 ND 1.23 ± 0.04 8.70 ± 7.9
Nicardipine (μM)
1.29 ± 0.6
ND
0.59 ± 0.4
0.39 ± 0.4
  • ND, not determined due to undetectable enzyme inactivation.